Drug Shortages Highlight the Need for Expanded Treatment Options for Syphilis
- PMID: 37390811
- DOI: 10.1093/cid/ciad396
Drug Shortages Highlight the Need for Expanded Treatment Options for Syphilis
Conflict of interest statement
Potential conflicts of interest. S. A. reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Pfizer; and support for attending meetings and/or travel from Pfizer and MSD. C. G. reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing. or educational events from Gilead, ViiV, MSD, and Jansen; and support for attending meetings and/or travel from Gilead, ViiV, MSD, and Jansen. A. G. reports consulting fees from Myland and Jansen; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Gilead and ViiV; payment for expert testimony from Jansen; support for attending meetings and/or travel from Gilead, ViiV, and MSD. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial.Clin Infect Dis. 2023 Sep 11;77(5):779-787. doi: 10.1093/cid/ciad278. Clin Infect Dis. 2023. PMID: 37157863 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
